Jim Cramer sees there was a triple-threat combination of events out there that is bringing the market higher. Could it be impacting your portfolio?» Read More
The widespread use of a combination of drugs that include Gilead Sciences Inc's Sovaldi, known generically as sofosbuvir, will nonetheless be a significant cost for the U.S. healthcare system, researchers wrote. Sovaldi's initial $84,000 price drew widespread criticism last year, and insurers have since pressed Gilead and rival AbbVie Inc to offer steep...
Louis Navellier's Squawk Box Platinum Portfolio is already up 20 percent this year. Here's his next move.
NEW YORK, March 15- As drugmakers develop new medicines to battle a liver disease epidemic, they have created an urgent need for better diagnostics to select patients for treatment and assess their drugs' effectiveness. About 30 percent of people in the U.S. now suffer from fatty liver diseases, such as NASH, fueled by obesity, diabetes and over-indulgent...
Copycat biotech drugs in the U.S. market could cut prices of expensive medications by 40 percent to 50 percent, said a top CVS Health exec.
WASHINGTON, March 11- The entry of copycat biotech drugs into the U.S. market could cut prices of expensive medications by 40 percent to 50 percent, depending on the level of competition among drugmakers, a top executive at CVS Health Corp told Reuters. CVS is one of the largest U.S. pharmacy benefit managers and, along with rival Express Scripts, has put...
Spending on prescription drugs in the U.S. rose 13.1% in 2014, the biggest increase in more than a decade, according a report from Express Scripts.
Avago Technologies, Facebook and Michael Kors are among 9 companies that are growing the fastest in America, USA Today reports.
Jim Cramer predicted bearish days ahead for March. But that doesn't mean you can't make money! Cramer gives his bear market survival guide of stocks.
Data from eVestment show which stocks are poised to make a big run in 2015, based on the names institutional investors have already been trading.
If the bullish trend remains intact, here are the stocks that could lift the Nasdaq to 6,000.
In the Nasdaq composite, financial, consumer services and health-care sectors have seen their weightings more than double.
These seven Nasdaq stocks are still attractive despite the index nearing 5,000, USA Today reports.
The Nasdaq Composite has yet to reach record territory, but as it marches towards those milestones, there are a handful of powerful stocks at play.
The market is reaching new highs, but could we really be in a bubble? Jim Cramer finds out.
LOS ANGELES, Feb 19- As U.S. drugmakers face growing resistance to the high price of cutting-edge treatments, a handful of companies are working on a new payment model that rewards them for the long-term performance of their medicines. They include BioMarin Pharmaceutical Inc in San Rafael, California, and Sangamo BioSciences Inc in Richmond, California.
Feb 17- CVS Health Corp, the second-largest U.S. pharmacy chain operator, has warned that a new class of drugs being developed to lower "bad" cholesterol could cost the U.S. healthcare system as much as $150 billion per year. The new class of cholesterol drugs called PCSK9 inhibitors could be priced in the range of $7,000- $12,000 per year, CVS said.
An exclusive analysis of more than 2.5 million portfolios tracked by SigFig found that, on average, women outperformed male investors.
With overseas quiet on Tuesday, Jim Cramer finally was able to ignore the noise and recommends a few gem stocks that are real winners.
NEW YORK, Feb 10- Gilead Sciences Inc said on Tuesday it expects the number of hepatitis C patients treated in Europe with its Sovaldi drug to increase dramatically this year, and that approvals for the newer combination pill, Harvoni, could come quickly. The company, which has come under intense criticism in the United States for the high price of its treatments...
LONDON, Feb 10- Global health charity Medecins du Monde launched a legal challenge on Tuesday to a European patent held by U.S. drugmaker Gilead Sciences Inc which it accused of charging "exorbitant" prices for a hepatitis C drug. According to World Health Organization data, as many as 150 million people worldwide live with chronic hepatitis C infection, most of...